Therapy of cryptococcosis with a combination of flucytosine and amphotericin B.
In a prospective study from May 1971 to November 1973, 20 consecutive patients with a diagnosis of disseminated cryptococcosis were treated for six weeks with a combination of amphotericin B (20 mg daily) intravenously and flucytosine (150 mg/kg daily) orally. Fifteen patients has culturally docummented Cryptococcus neoformans meningitis, and three died of infection early in therapy. Of the remaining 12 patients, eight were alive and well eight to 34 months after therapy, and four died of other causes. None of the surviving patients has relapsed. Hematologic complications developed in nine patients, three of whom had no underlying lymphoreticular disorder or therapy with known cytotoxic agents. Renal insufficiency of mild degree occurred in only six patients. A shorter period of hospitalization and reduction in toxicity of amphotericin B suggest that combined therapy is a safe and efficacious alternative to other regimens.
D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D003453:Cryptococcosis / Q000188:drug therapy* / Q000378:metabolism; D003596:Cytosine / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D005260:Female; D005437:Flucytosine / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008297:Male; D008581:Meningitis / Q000188:drug therapy / Q000378:metabolism; D008875:Middle Aged; D011446:Prospective Studies
D000666:Amphotericin B; D003596:Cytosine; D005437:Flucytosine